ADCX-020 / Adcytherix - LARVOL DELTA

French antibody biotech draws in $122M for end-of-year clinical push (FierceBiotech) - "With the new cash, the company plans to file an investigational new drug application in the U.S.—plus submit clinical trial applications in the U.K., Canada and Europe—by the end of the year for lead candidate ADCX-020."

Financing • IND • New trial • Oncology